Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

PURPOSE: We investigated the population pharmacokinetics and exposure-response relationship of nilotinib in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase. METHODS: Nilotinib was given at 300 mg or 400 mg twice daily. Serum concentration data (sparse and full pharmacok...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Eur J Clin Pharmacol
Hoofdauteurs: Larson, Richard A., Yin, Ophelia Q. P., Hochhaus, Andreas, Saglio, Giuseppe, Clark, Richard E., Nakamae, Hirohisa, Gallagher, Neil J., Demirhan, Eren, Hughes, Timothy P., Kantarjian, Hagop M., le Coutre, Philipp D.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2011
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5557053/
https://ncbi.nlm.nih.gov/pubmed/22207416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00228-011-1200-7
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items